You searched for "ocular"
Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease
Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...Reichert Ocular Response Analyser G3
Make a more confident glaucoma risk assessment with Corneal Hysteresis. ORA® G3 is the only tonometer that measures Corneal Hysteresis (CH), a superior predictor of glaucoma progression. CH is an indication of the biomechanical properties of the cornea differing from...
Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma single institutional experience
Ocular adnexal lymphomas constitute 2% of all non-Hodgkin’s disease and 5-15% of all extranodal lymphomas and are usually localised, low-grade and of B-cell origin. This opens them up to potential treatment with a systemic monoclonal antibody-based drug (rituximab) directed at...
Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases
This is a retrospective study of patients with ocular surface inflammatory diseases (OSIDs) treated with IKERVIS in a single centre between 2016 to 2019 with at least six months follow-up. Clinical outcome was defined as successful (resolved or stable disease),...
Low dose steroids for ocular dry eye disease in graft vs. host disease
This double-masked randomised clinical trial compared the response of dry eye disease (DED) to treatment with topical steroids in patients with and without graft vs. host disease (GVHD). Forty-two patients in a single centre (n=21 with and n=21 without GVHD)...
Ocular hypertension following intravitreal steroid injections: a comparative study between triamcinolone-acetonide and dexamethasone-implant
This was a retrospective observational study of steroid response following 1549 intravitreal steroid (TA and Dex) injections. One thousand and seventy-five eyes of 897 patients were reviewed. Glaucoma patients, glaucoma suspects, uveitis, trauma, and cases with less than one month...Understanding spaceflight-associated neuro-ocular syndrome (SANS): what do we know?
Introduction Formerly known as visual impairment and intracranial pressure syndrome (VIIP), space-related neuro-ocular syndrome (SANS) is defined by a collection of ophthalmic and neurological findings in astronauts after long-term spaceflight [1]. Changes in the eyeball, such as hyperopic shift, during...
High rate of conversion from ocular hypertension (OH) to glaucoma (UG) in subjects with uveitis
5 June 2023
| Jonathan Chan
|
EYE - Glaucoma
|
glaucoma, infection, inflammation, treatment medical, treatment surgery
This is a retrospective study from Auckland over a 10-year period including 188 eyes of 139 subjects with either OH or UG and were included for analysis with a mean follow-up of 9.9 years. The most common uveitis causes were...
Histopathology-guided management of ocular surface squamous neoplasia (OSSN) with corneal stromal or scleral invasion using ruthenium-106 plaque brachytherapy
11 January 2024
| Jonathan Chan
|
EYE - Pathology, EYE - Oncology
|
conjunctiva, eye (globe), pathology, salivary gland
This is a retrospective interventional consecutive case series of 42 eyes of 42 patients with OSSN with histopathologically proven corneal stromal and / or scleral invasion following excision biopsy. The mean tumour basal diameter was 9.3mm and thickness of 3.1mm...
Acetylcholine receptor antibodies in the diagnosis of ocular myasthenia gravis at the Manchester Royal Eye Hospital
3 August 2023
| Nouf Alnafisee, Joanna M Jefferis
|
EYE - Neuro-ophthalmology
Myasthenia gravis (MG) is the commonest autoimmune condition to affect the neuromuscular junction. In the UK, its prevalence is 15 per 10,000 [1,2] and recent studies have shown that rates are steadily increasing [3,4]. Aims of this audit The aim...
Gene therapy for inherited retinal disease: the Manchester Ocular Gene Therapy Group MDT service
4 August 2021
| Jane Ashworth, Tsveta Ivanova, Susmito Biswas, Assad Jalil, Georgina Hall, Rebecca Redmond, Graeme CM Black (Prof), William Newman, Neil Parry, Jane CB Gray, Charlotte Skitterall
|
EYE - Paediatrics, EYE - Vitreo-Retinal, EYE - General
The authors describe the process set up in Manchester for the optimum delivery and assessment of a new gene therapy treatment for patients with RPE65 IRD. Inherited retinal dystrophies (IRDs) are the second commonest cause of severe visual impairment in...
